Juvelook vs Sculptra: Two Collagen Injectables, Compared
Same goal, different particles, very different US status. Here is how PDLLA and PLLA actually compare.
Two injectables, one shared promise: your own skin builds the collagen, not the syringe.
That is where the overlap ends. Sculptra is made of poly-L-lactic acid (PLLA). Juvelook is built on poly-D,L-lactic acid (PDLLA) blended with hyaluronic acid. The names sound like cousins because the chemistry is — but the particles, the feel of the treatment and, above all, the regulatory status in the US are different. If you are weighing the two before a Seoul trip or a dermatologist visit, here is how they actually compare.
What are they, and how do they work?
Both belong to a group called collagen biostimulators. Instead of filling a space with gel, they place tiny particles under the skin and let your body respond to them. The response — a controlled, low-grade inflammatory reaction — is what produces new collagen over weeks and months.
Sculptra (PLLA). The FDA describes PLLA as a biodegradable, biocompatible man-made polymer that is given in a series of injections over several months. Its effects become increasingly apparent over several weeks and, per the FDA, may last up to two years.
Juvelook (PDLLA + HA). PDLLA is a racemic mix of D- and L-lactic acid. That makes it an amorphous polymer with an irregular chain, where PLLA is semi-crystalline. A 2024 consensus paper on PDLLA microspheres describes the particles as spherical and porous, with an internal structure the authors liken to a scaffold for new tissue. Juvelook pairs those particles with non-cross-linked hyaluronic acid, so the product also hydrates the skin it sits in.
How fast do they work?
The mechanism is the same family. The timeline is where you feel the difference.
According to the PDLLA consensus paper, myofibroblasts appear around the microspheres by about 2 weeks, extracellular type I collagen by week 4, and collagen synthesis inside the particles by week 20. Some results show within the first few weeks, and the paper puts the best moment for a final evaluation at 2 to 6 months after the last session. Its authors suggest that differences in particle shape may contribute to an earlier onset of perceived effects, compared with PLLA.
PLLA is slower to declare itself. A systematic review of 11 randomized trials found the earliest significant measured change — a gain in dermal thickness — at week 12, with benefits reported for up to 25 months.
Read those two timelines carefully. They come from different studies, different products and different measurements. They are not a head-to-head race, and no trial we found pits Juvelook against Sculptra directly.
Juvelook vs Sculptra: side by side
| Sculptra | Juvelook | |
|---|---|---|
| Core material | PLLA (L-isomer only, semi-crystalline) | PDLLA (D and L isomers, amorphous) plus non-cross-linked HA |
| Particle behavior | Solid, irregular particles | Porous, sponge-like microspheres |
| Typical protocol | 1 to 4 sessions, about 3 to 4 weeks apart in most trials | Protocols vary by clinic and product version |
| When you notice it | Gradual; measured change by about week 12 | Some change in the first weeks; fullest effect around 2 to 6 months |
| How long it lasts | Up to about 2 years per the FDA; studies report up to 25 months | PDLLA studies in the consensus paper show scores above baseline at 24 months |
| Quality of evidence | 11 RCTs, none rated low risk of bias | Limited aesthetic trials; consensus and case reports |
| US status | FDA-approved, with specific indications | No FDA approval found |
The pattern: Sculptra has the deeper trial record and a clear US regulatory pathway. Juvelook has an additional hydration component and is the one you will mostly meet in Korea.
Who is each one for?
Neither treatment is a fix for a single line. Both are for overall quality and support — skin that has lost firmness, texture or volume gradually.
- Sculptra fits you if you want to rebuild support across a broader area, such as the midface, and you are planning for a series of visits over a few months. The FDA approval history matters here: according to the systematic review, Sculptra was approved in 2004 for facial lipoatrophy in people with HIV, extended in 2009 to deep nasolabial folds and wrinkles in the same population, and in 2023 to fine cheek wrinkles. If you are in the US, it is the one you can get from a licensed injector. For the volume-loss use case, our guide to Sculptra vs filler for hollow cheeks goes deeper.
- Juvelook fits you if you are in Seoul and your concern is texture, crepey skin or early firmness loss — the kind of "skin booster" territory. Our Juvelook guide covers what a session looks like, and Rejuran vs Juvelook explains where it sits next to polynucleotide boosters.
Who should skip both. The PDLLA consensus paper lists these absolute contraindications: active infection or inflammation at the site, active collagen disorders, permanent fillers in the same plane, pregnancy and active herpes near the area. Relative contraindications include autoimmune disease, anticoagulation, liver dysfunction, lactation and recent surgery at the site. Tell your injector about all of it.
What can go wrong?
Both are well-tolerated when done correctly, and both share one signature risk: nodules.
- Common and minor: bruising, tenderness and swelling. The PDLLA consensus paper calls severe events rare. The PLLA systematic review reports mostly mild to moderate events — bruising, hematoma, tenderness, edema, erythema.
- Nodules: the PLLA review reports nodules in several trials, including one with subcutaneous nodules in 41% of PLLA patients. The authors attribute most adverse events to the injection procedure and post-treatment care rather than to the material itself. The PDLLA paper says the same: nodules are mainly linked to improper technique, and granulomas to an exaggerated inflammatory response.
- Aftercare: the PDLLA panel recommends massage twice daily for 3 to 5 days to help distribute the product. Follow whatever your clinic tells you — protocols differ.
Here is the honest caveat on the evidence. The PDLLA consensus came from ten Brazilian physicians, several with financial ties to PDLLA manufacturers or distributors, and the authors themselves state that clinical trials of PDLLA for aesthetic use are limited. The one open-access Juvelook-specific paper we found is a single-patient case report with 18 days of follow-up. And the PLLA review concludes that all findings rest on low-quality evidence. That is a real limit on what anyone can promise you. Results vary.
Can you get them in the US?
Sculptra: yes. It is FDA-approved, and a board-certified dermatologist or plastic surgeon can administer it. The FDA's page on approved fillers groups fillers by material — hyaluronic acid, calcium hydroxylapatite, PLLA and PMMA. PDLLA is not among them.
Juvelook: we found no FDA approval. It is sold through Korean clinics, which is why Seoul is where most US searchers end up looking for it. If a US clinic offers a PDLLA product, ask exactly which product it is and what its US regulatory status is. Do not accept "same thing" as an answer. The FDA also notes that unapproved versions of Juvederm have been sold in the US, including by online retailers — a reminder to ask where any filler came from.
If you are planning a visit, our guide to choosing a skin clinic in Seoul as a foreigner lays out what to ask before you book.
The Glass Beauty Seoul Take
These are not rivals. They are two answers to the same question, asked at different levels of evidence.
Sculptra is the safer default if you are in the US. It has a regulatory pathway, a trial record and a long clinical history. Juvelook is the more interesting option if you are in Seoul, with a different particle design and an added hydration layer — and a thinner evidence base that you should hold in your head while you decide. Neither one gives instant results. Both ask for patience and a skilled injector, and the injector matters more than the brand name.
So skip the "which is better" thread. Ask a better question: what is my skin actually doing, and who is qualified to treat it? If you have been circling these two for months, book the consultation — and bring this table.
Glass Beauty Seoul is building the guide to Korean skin treatments for the rest of the world. Follow along as we break down every treatment before you book a flight.
Questions.
Is Juvelook the same as Sculptra?+
No. Sculptra is poly-L-lactic acid (PLLA). Juvelook is poly-D,L-lactic acid (PDLLA) combined with non-cross-linked hyaluronic acid. Both are collagen biostimulators, but the particles differ in structure and the products differ in regulatory status.
Is Juvelook FDA-approved?+
We found no FDA approval for Juvelook. The FDA's approved-filler page lists hyaluronic acid, calcium hydroxylapatite, PLLA and PMMA materials, and PDLLA is not among them. Sculptra, a PLLA product, is FDA-approved for specific indications.
How long do Juvelook and Sculptra last?+
The FDA says PLLA effects may last up to two years, and a systematic review reports benefits for up to 25 months. A PDLLA consensus paper reports scores above baseline at 24 months. Results vary by person and protocol.
Which is better, Juvelook or Sculptra?+
No trial compares them head to head. Sculptra has the larger trial record and a US regulatory pathway. Juvelook adds a hydration component and is mostly available in Korea, with a thinner evidence base. The right choice depends on your skin concern and your injector.
Can either treatment cause nodules?+
Yes. Nodules are the best-known risk of collagen biostimulators. Studies attribute most of them to injection technique and aftercare rather than the material itself. Choose a qualified injector and follow your clinic's aftercare instructions.